This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Trump Proposes 2020 Budget: ETFs to Top & Flop
by Sweta Killa
Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.
Best and Worst ETFs of Last Week
by Sweta Killa
After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed threats of global slowdown.
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
Why These Small Cap Biotech ETFs are Soaring
by Neena Mishra
These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.
ETFs from Best & Worst Zones of Q1
by Sweta Killa
American equities are on track for the worst quarter since 2015.
3 Sector ETFs That Gained Double-Digits in Q1
by Sweta Killa
We have highlighted three sectors ETFs that have have easily survived the market turbulence in the first quarter, gaining in double-digits.
Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment
by Neena Mishra
CNCR ETF is up about 30% this year; here is what investors need to know about immunotherapy and the ETF (CNCR, IBB).
3 ETF Areas Up At Least 15% This Year
by Sanghamitra Saha
The S&P 500 may offer paltry returns so far this year but these ETF areas remained strong.
5 Best ETF Charts of Q4 Earnings
by Sweta Killa
Several equity ETFs have impressed with their performances and generated handsome returns over the trailing one month even after being hit by the market rout.
The Zacks Analyst Blog Highlights: SPDR S&P Internet ETF, Loncar Cancer Immunotherapy ETF, VanEck Vectors Steel ETF and Amplify Online Retail ETF
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SPDR S&P Internet ETF, Loncar Cancer Immunotherapy ETF, VanEck Vectors Steel ETF and Amplify Online Retail ETF
4 Market-Beating Sector ETFs & Stocks of February
by Sweta Killa
A few sectors have easily survived the market rout and are crushing the broad market this month.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Biotech ETF (CNCR) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Top and Flop ETFs of January 2018
by Sanghamitra Saha
Inside the best and worst-performing ETFs of January.
5 Best-Performing Stocks of the Top ETF of January
by Sweta Killa
Inside the top performing stocks of the top biotech ETF of January.
M&A Waves Pushing Biotech ETFs Higher
by Sweta Killa
The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.
Top-Ranked ETFs Crushing the S&P 500 to Start 2018
by Sweta Killa
The latest pullback could be just a pause in the Wall Street rally as traders took the chance to book some profits after a record run.
5 Secret Santa ETFs & Stocks Ahead of Christmas
by Sweta Killa
While most of the stocks and ETFs have been surging over the past one month, there are some hidden gems that could surprise investors with big returns this Christmas.
Value Biotech ETFs to Buy Now
by Sanghamitra Saha
A few reasons why you should buy value biotech ETFs for 2018
The Zacks Analyst Blog Highlights: Loncar Cancer Immunotherapy, First Trust Mid Cap Growth AlphaDEX, iShares Dow Jones Transportation Average Index, iShares Edge MSCI Multifactor Global and Barron's 400
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Loncar Cancer Immunotherapy, First Trust Mid Cap Growth AlphaDEX, iShares Dow Jones Transportation Average Index, iShares Edge MSCI Multifactor Global and Barron's 400
5 ETF Picks for October
by Sanghamitra Saha
A few ETF choices for the month of October.
Top and Flop Sector ETFs of Q3
by Sanghamitra Saha
Inside the best and worst performing ETF areas of the third quarter.
Should You Keep Your Portfolio Healthy with Biotech ETFs?
by Sanghamitra Saha
Biotech ETFs are riding high on research and developments and FDA approvals.
Biotech ETFs Soar on Gilead-Kite Deal
by Sanghamitra Saha
Gilead Sciences boosted the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma.